Overview
Sponsor-declared trial summary
Perioperative anxiety in children scheduled for an elective circumcision, dental care or tonsillectomy/adenoidectomy in day-care
The goal of this study is, first, to evaluate the need for midazolampremedication in pediatric day-care patients induced by inhalational anesthesia, and second, to compare the efficacy and safety between anxiolysis by multimedia with an IPAD versus (no anxiolysis) and versus anxiolysis by premedication with midazolam p…
Key facts
- Sponsor
- UZ Brussel
- Participant type
- Pediatric, Patients
- Age range
- 0-17 years
- Gender
- Male and Female
- Therapeutic area
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
- Trial duration
- 31 Jan 2020 → ongoing
- Decision date (initial)
- 2024-07-10
- Transition trial
- Yes
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
External identifiers
- EU CT number
- 2024-514642-37-00
- EudraCT number
- 2019-004671-39
Trial design
CTIS Part I — objectives, methods, condition coding
Main objective
Scope: Efficacy, Therapy, Safety
The goal of this study is, first, to evaluate the need for midazolampremedication
in pediatric day-care patients induced by inhalational
anesthesia, and second, to compare the efficacy and safety between
anxiolysis by multimedia with an IPAD versus (no anxiolysis) and versus
anxiolysis by premedication with midazolam prior to anestheticinduction.
Our hypothesis is that Tablet/IPAD distraction could result in equal or
better anxiety control in comparison to the standard care with
midazolam-premedication.
The primary endpoint is reduction in level of anxiety perioperative,
primarily during induction in children between one and eight years of
age in day-care-surgery.
Secondary objectives 8
- Anxiety reduction perioperative on daycare, holding and recovery
- the incidence of stressful anesthetic mask-inductions
- The incidence of laryngeal spasms or bronchospasm
- Parental satisfaction
- parental stress/anxiety level
- Postoperative anxiety
- Postoperative POCIS
- RASS-score evaluation of sedation or possible negative behavior preoperative after midazolam administration
Conditions and MedDRA coding
Perioperative anxiety in children scheduled for an elective circumcision, dental care or tonsillectomy/adenoidectomy in day-care
Eligibility criteria
Principal inclusion / exclusion criteria as submitted by sponsor
Inclusion criteria 4
- Age ≥ 1 year and <8 years old
- ASA 1 or 2
- Elective circumcision, tonsillectomy or adenoidectomy, dental care procedure in day-care
- Written informed consent by the legal parents or caretaker
Exclusion criteria 14
- Parents of the patient wish not to participate with the study
- Parents are not able to give informed consent (language barrier, legally incapable)
- A contraindication for the use of premedication with midazolam
- A known allergy to midazolam
- A contraindication for premedication in general
- A contraindication for the use of a gas-induction/gas-anesthesia
- A contraindication for the use of sevoflurane
- A known mental retardation of the child
- Preoperative behavioral disturbances and psychiatric disorders
- Any use of psychoactive medication
- A known photosensitive epilepsy
- A previous operation within 3 months of the time of scheduled operation
- Any other contraindication for the use of the study medication
- Previous history of multiple surgery (>3)
Endpoints
Primary and secondary outcome measures (English text)
Primary endpoints 1
- Primary endpoints are the difference in perioperative anxiety between the two groups measured with mYpas-score and parental-scoring with the 5-point anxiety scale.
Secondary endpoints 7
- Stressful inductions (anesthetic satisfaction) Definition of stressful anesthetic inductions will be qualified by scaling and noted by the anesthesiologist, directly post-induction. XML File Identifier: Mmsidp0h9a5a/NwZENxH2Odvq/w= Page 15/25 1. Cooperative Smooth Induction: no crying, no unrest 2. Passive induction: crying, no unrest 3. Anxious induction: crying and unrest 4. Combative induction: total hysteric 2. Parental scoring for anxiety of the patient
- Parental scoring for anxiety of the patient will be done by the following the 5-point anxiety scale used: 1. Happy (playing) 2. Happy/little worried (playing cautiously) 3. Worried (no playing, silently) 4. Anxious (crying) 5. Hysterical (crying and screaming) Parental scoring will be done, on the daycare preoperative, on the holding, postoperative on the recovery.
- Respiratory postoperative complications Scored directly post-induction and post detubation - Laryngospasm: Four-point scale (17) 1. No Laryngospasm 2. Mild laryngospasm (relieved by jaw thrust and 100% oxygen) 3. Moderate laryngospasm (relieved by 100% oxygen and positive pressure ventilation) 4. Severe laryngospasm (relieved by succinylcholine and intubation)
- Bronchospasm/wheezing 1. Yes 2. No • In absence of a scale
- Parental Satisfaction on the anxiety-management perioperative: measured on holding, after induction, recovery, postop daycare unit. 1. Extremely satisfied 2. Satisfied 3. Neutral 4. Unsatisfied 5. Extremely Unsatisfactory
- Postoperative POCIS-Score by leaving the recovery. POCIS is more suitable for young children then the traditional VAS-score (18) See Appendix III of the protocol
- Preoperative sedation or negative behavior Evaluation of sedation or possible negative behavior preoperative after midazolam is done by the RASS-score. (19) See Appendix III of the protocol
Investigational products
Investigational medicinal products (IMPs), comparators, placebo, auxiliary
Test 2
Midazolam Rowa 2.5 mg oromucosal solution
PRD10319239 · Product
- Active substance
- Midazolam
- Pharmaceutical form
- OROMUCOSAL SOLUTION
- Route of administration
- ORAL USE
- Max daily dose
- 1 mg/kg milligram(s)/kilogram
- Max total dose
- 1 mg/kg milligram(s)/kilogram
- Max treatment duration
- 1 Day(s)
- Authorisation status
- Authorised
- ATC code
- N05CD08 — MIDAZOLAM
- Marketing authorisation
- PA0074/099/001
- MA holder
- ROWA PHARMACEUTICALS LIMITED
- MA country
- Ireland
- Paediatric formulation
- Yes
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
BUCCOLAM 2.5 mg oromucosal solution
PRD8810399 · Product
- Active substance
- Midazolam
- Pharmaceutical form
- OROMUCOSAL SOLUTION
- Route of administration
- ORAL
- Max daily dose
- 1 mg/kg milligram(s)/kilogram
- Max total dose
- 1 mg/kg milligram(s)/kilogram
- Max treatment duration
- 1 Day(s)
- Authorisation status
- Authorised
- ATC code
- N05CD08 — MIDAZOLAM
- Marketing authorisation
- EU/1/11/709/001
- MA holder
- NEURAXPHARM PHARMACEUTICALS S.L.
- MA country
- EU
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
UZ Brussel
- Sponsor organisation
- UZ Brussel
- Address
- Laarbeeklaan 101
- City
- Jette
- Postcode
- 1090
- Country
- Belgium
Scientific contact point
- Organisation
- UZ Brussel
- Contact name
- Virgini Van Buggenhout
Public contact point
- Organisation
- UZ Brussel
- Contact name
- Domien Vanhonacker
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Belgium | Ongoing, recruiting | 150 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Belgium | 2020-01-31 | 2020-01-31 |
Results and documents
Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial
Documents 10 files
Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.
| Type | Title | Version |
|---|---|---|
| Protocol (for publication) | D1_protocol_2024-514642-37-00_redacted | 5 |
| Recruitment arrangements (for publication) | K1_recruitment arrangements_2024-514642-37-00_Statement_Not applicable_redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF adults FR_2024-514642-37-00_redacted | 3 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF adults NL_2024-514642-37-00_redacted | 3 |
| Subject information and informed consent form (for publication) | L2_other subject information material GDPR FR_2024-514642-37-00_redacted | 2 |
| Subject information and informed consent form (for publication) | L2_other subject information material GDPR NL_2024-514642-37-00_redacted | 2 |
| Summary of Product Characteristics (SmPC) (for publication) | E2_SmPC Buccolam | 1 |
| Summary of Product Characteristics (SmPC) (for publication) | E2_SmPC_Midazolam | 1 |
| Summary of Product Characteristics (SmPC) (for publication) | E2_SmPC_Midazolam UK | 1 |
| Summary of Product Characteristics (SmPC) (for publication) | E2_SmPC_Midazolam US | 1 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-06-25 | Belgium | Acceptable 2024-07-02
|
2024-07-10 |